Chronic rhinosinusitis with nasal polyps (CRSwNP) inflammatory endotypes are associated with long-term air pollutant and allergen exposure.

Top-line data from Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps expected in ...

USA: In a recent exposure-matched study, researchers found that long-term exposure to fine particulate matter (PM2.5) may ...

We are pleased to accelerate our guidance on several near-term events, including the top-line data readout from our Phase 2 clinical trial of verekitug in patients with CRSwNP, expected in the thi ...

Operating profit / (loss): Operating profit was $10.6 million for the three months ended 31 March 2025, compared to ($48.4) ...

GSK to present data from across its respiratory portfolio at 2025 ATS International Congress in San Francisco: London, UK Monday, May 5, 2025, 10:00 Hrs [IST] GSK plc announced da ...

Topical deep delivery of corticosteroids into the sinonasal cavity improves symptoms and sleep in patients with chronic rhinosinusitis.

The next major data catalyst is expected in H2 2025, with data from a Phase 2 study in patients with chronic rhinosinusitis with nasal polyps ("CRSwNP"), although this is a small, 70-patient study ...

The candidate is currently being evaluated in two phase III studies — CEREN 1 and CEREN 2 — for treating patients with chronic rhinosinusitis with nasal polyps (CRSwNP). A phase II study is ...